Immunome, Inc. (IMNM) Free cash flow 2019–2025
Immunome, Inc. (IMNM) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$200.6MFY2025 · since FY2019: -$9.8M → -$200.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$200.6M | -70.1% |
| FY2024 | -$118.0M | -1304.5% |
| FY2023 | -$8.4M | +71.0% |
| FY2022 | -$28.9M | -58.1% |
| FY2021 | -$18.3M | -43.9% |
| FY2020 | -$12.7M | -29.4% |
| FY2019 | -$9.8M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice